Heart Failure

Discussing recent data from GALACTIC-HF with John Teerlink, MD, Executive Committee Chair for both GALACTIC-HF and COSMIC-HF.

New research from Weill Cornell Medicine is revealing more about the impact of social determinants on 90-day mortality following heart failure hospitalization.

An analysis of 60,000-plus patients over 2 decades suggests consumption of olive oil could help reduce rate of CVD.

Investigators from Saint Louis University discuss a new comparison of 2 drug classes that could reduce the risk of adverse cardiovascular events.

A discussion with Paul W. Armstrong of the University of Alberta, on the pandemic's effect on common ICU conditions.

Paul W. Armstrong, MD, joins to discuss the virtual cardiology sessions, as well as his team's new findings for vericiguat in high-risk heart failure.

New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.

A look at the state of cardiometabolic care based on research at ACC.20/WCC from a fourth-year medical student.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

Glucagon-like receptor agonists did not reduce the rate of hospitalization for heart failure as much as SGLT2 inhibitors did.

Patients of both sexes and differing levels of LVEF reported similar reductions in NT-proBNP when treated with the combination therapy, versus lone valsartan.

New secondary analsysis from the large-scale heart failure trial shows continued benefit of the SGLT2 inhibitor.

A heart failure and transplant cardiologist assesses the new study findings.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

New VICTORIA findings show the novel therapy may reduce risk of severe outcomes among high-risk patients with HFrEF.

A study’s proposed findings of increased coronavirus risk shows how presenting half of a fact can influence our care during a pandemic.

How cardiovascular experts have been communicating with international colleagues to inform local care response.

An ACC board member explains the major cardiology college's decision to move the meeting online during the COVID-19 pandemic.

The Mount Sinai expert and ACC late-breaking presentation panelist highlights her most anticipated trial data and discussions in the upcoming meeting.

Muthiah Vaduganathan, MD, MPH, discusses how research of the add-on drug class will continue to evolve into 2021.

A new review from investigators at Columbia University details topics from common comorbidities to potential treatments.

New data from ACC.20/WCC indicates low birth weight in infants could indicate mothers who are at increased risk of heart failure later in life.